| Discovery cohort | Validation cohort | Control |
---|---|---|---|
Number | 100 | 81 | 32 |
Age, years | 69 (61, 75)* | 72 (66, 79.5)* | 61 (43, 67) |
Male | 86 (86)* | 70 (86)* | 18 (56) |
Ever-smokers | 91 (91)* | 71 (88)* | 8 (25) |
%FVC | 89.5 (73.7, 101.4) | 79.5 (69.5, 89.2) | Â |
%DLCO | 42.7 (35.2, 53.9) | 45.1 (33.4, 57.1) | Â |
CPI | 47.4 (37.3, 56.3) | Â | Â |
PaO2, Torr (n = 96) | 82.7 (76.4, 89.1) | 81.7 (73.8, 88.6) |  |
Six-minute walk distance, meter (n = 97) | 463 (407, 520) | 479.5 (421, 539) |  |
Lowest SpO2 during the six-minute walk test, % (n = 97) | 88 (82, 92) | 89 (83, 91) |  |
KL-6, IU/L | 805 (607, 1260) | 909 (595, 1600) | Â |
SP-D, ng/mL | 236.5 (132.3, 348) | 206.5 (121.6, 339.3) | Â |
LDH, IU/L | 212 (193.8, 238.5) | 223 (187.5, 249) | Â |
CPFE | 30 (30) | Â | Â |
Anti-fibrotic drug use at baseline | 2 (2) | 0 (0) | Â |
Anti-fibrotic drug use more than 6Â months during the observational period | 51 (51) | 47 (58) | Â |
Mortality | 52 (52) | 19 (23) | Â |
Observation period, months | 41 (19, 68) | 19 (12, 27) | Â |